Ping-Ping Cao1, Zhi-Chao Wang2, Robert P Schleimer3, Zheng Liu2. 1. Department of Otolaryngology-Head and Neck Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China; Division of Allergy-Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois. 2. Department of Otolaryngology-Head and Neck Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China. 3. Division of Allergy-Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Abstract
OBJECTIVE: Chronic rhinosinusitis (CRS) is a heterogeneous disorder with distinct pathophysiologic mechanisms. Based on transcription factor expression and cytokine production patterns in different innate lymphoid cell (ILC) types, in parallel with those of adaptive CD4+ T-helper (TH) cells and CD8+ cytotoxic T (Tc) cells, new perspectives on endotypes of patients are emerging for the immune response deviation into type 1 (orchestrated by ILC1s and Tc1, and TH1 cells), type 2 (characterized by ILC2s and Tc2 and TH2 cells), and type 3 (mediated by ILC3s and Tc17 and TH17 cells). In addition, cluster analysis has been applied to endotyping of CRS in recent years, which has provided additional novel insights into CRS pathogenesis. This review assessed pathologic mechanisms of CRS based on type 1, 2, and 3 immune responses and how they inform us to begin to understand CRS endotypes. This review also assessed recent cluster analysis studies of CRS endotypes. The impact of endotype on therapeutic management of CRS also is summarized. DATA SOURCES: Review of published literature. STUDY SELECTIONS: Relevant literature concerning CRS endotypes and possible underlying mechanisms was obtained from a PubMed search and summarized. RESULTS AND CONCLUSION: CRS with and without nasal polyps are composed of distinct endotypes with distinct deviated immune responses, pathogenic mechanisms, and different responses to medical and surgical treatment. An endotype of CRS with prominent type 2 immune responses is the best-studied endotype and generally can benefit from treatment with steroids and specific type 2 disrupting biologics.
OBJECTIVE:Chronic rhinosinusitis (CRS) is a heterogeneous disorder with distinct pathophysiologic mechanisms. Based on transcription factor expression and cytokine production patterns in different innate lymphoid cell (ILC) types, in parallel with those of adaptive CD4+ T-helper (TH) cells and CD8+ cytotoxic T (Tc) cells, new perspectives on endotypes of patients are emerging for the immune response deviation into type 1 (orchestrated by ILC1s and Tc1, and TH1 cells), type 2 (characterized by ILC2s and Tc2 and TH2 cells), and type 3 (mediated by ILC3s and Tc17 and TH17 cells). In addition, cluster analysis has been applied to endotyping of CRS in recent years, which has provided additional novel insights into CRS pathogenesis. This review assessed pathologic mechanisms of CRS based on type 1, 2, and 3 immune responses and how they inform us to begin to understand CRS endotypes. This review also assessed recent cluster analysis studies of CRS endotypes. The impact of endotype on therapeutic management of CRS also is summarized. DATA SOURCES: Review of published literature. STUDY SELECTIONS: Relevant literature concerning CRS endotypes and possible underlying mechanisms was obtained from a PubMed search and summarized. RESULTS AND CONCLUSION:CRS with and without nasal polyps are composed of distinct endotypes with distinct deviated immune responses, pathogenic mechanisms, and different responses to medical and surgical treatment. An endotype of CRS with prominent type 2 immune responses is the best-studied endotype and generally can benefit from treatment with steroids and specific type 2 disrupting biologics.
Authors: Mahboobeh Mahdavinia; Roderick G Carter; Christopher J Ocampo; Whitney Stevens; Atsushi Kato; Bruce K Tan; Robert C Kern; David B Conley; Rakesh Chandra; Kathryn E Hulse; Lydia A Suh; James E Norton; Anju T Peters; Leslie C Grammer; Lawrence B Schwartz; Robert P Schleimer Journal: J Allergy Clin Immunol Date: 2014-03-15 Impact factor: 10.793
Authors: S Feldman; R Kasjanski; J Poposki; D Hernandez; J N Chen; J E Norton; L Suh; R G Carter; W W Stevens; A T Peters; R C Kern; D B Conley; B K Tan; S Shintani-Smith; K C Welch; L C Grammer; K E Harris; A Kato; R P Schleimer; K E Hulse Journal: Clin Exp Allergy Date: 2017-01-26 Impact factor: 5.018
Authors: Philippe Gevaert; Lien Calus; Thibaut Van Zele; Katrien Blomme; Natalie De Ruyck; Wouter Bauters; Peter Hellings; Guy Brusselle; Dirk De Bacquer; Paul van Cauwenberge; Claus Bachert Journal: J Allergy Clin Immunol Date: 2012-09-27 Impact factor: 10.793
Authors: Kim A Papp; Craig Leonardi; Alan Menter; Jean-Paul Ortonne; James G Krueger; Gregory Kricorian; Girish Aras; Juan Li; Chris B Russell; Elizabeth H Z Thompson; Scott Baumgartner Journal: N Engl J Med Date: 2012-03-29 Impact factor: 91.245
Authors: S Seshadri; D C Lin; M Rosati; R G Carter; J E Norton; L Suh; A Kato; R K Chandra; K E Harris; H W Chu; A T Peters; B K Tan; D B Conley; L C Grammer; R C Kern; R P Schleimer Journal: Allergy Date: 2012-07 Impact factor: 13.146
Authors: Robert J Lee; Guoxiang Xiong; Jennifer M Kofonow; Bei Chen; Anna Lysenko; Peihua Jiang; Valsamma Abraham; Laurel Doghramji; Nithin D Adappa; James N Palmer; David W Kennedy; Gary K Beauchamp; Paschalis-Thomas Doulias; Harry Ischiropoulos; James L Kreindler; Danielle R Reed; Noam A Cohen Journal: J Clin Invest Date: 2012-10-08 Impact factor: 14.808
Authors: Zachary M Soler; Frederick Yoo; Rodney J Schlosser; Jennifer Mulligan; Vijay R Ramakrishnan; Daniel M Beswick; Jeremiah A Alt; Jose L Mattos; Spencer C Payne; Kristina A Storck; Timothy L Smith Journal: Int Forum Allergy Rhinol Date: 2019-12-19 Impact factor: 3.858
Authors: Claire Gleadhill; Marlene M Speth; Isabelle Gengler; Katie M Phillips; Lloyd P Hoehle; David S Caradonna; Stacey T Gray; Ahmad R Sedaghat Journal: Eur Arch Otorhinolaryngol Date: 2020-08-04 Impact factor: 2.503
Authors: Brennan J Blight; Amarbir S Gill; Jorgen S Sumsion; Chelsea E Pollard; Shaelene Ashby; Gretchen M Oakley; Jeremiah A Alt; Abigail Pulsipher Journal: J Asthma Allergy Date: 2021-05-27